ArticleThe journal of headache and pain2022
Measuring interictal burden among people affected by migraine: a descriptive survey study.
Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Interictal burden in migraine: a systematic review of conceptual domains and measurement properties of instruments.The journal of headache and pain · 2026Pooled it
- Psychological transdiagnostic factors and migraine characteristics as predictors of migraine-related disability.The journal of headache and pain · 2025Trial
- Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.The journal of headache and pain · 2025Trial
- The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Trial
- Article
- Two-Year Outcomes and Interictal Burden After Treatment for Medication Overuse Headache.Journal of clinical medicine · 2026Article
- Cognitive Dysfunction in Migraine: Underlying Mechanisms and Clinical Implications.Current pain and headache reports · 2026Review
- The Relevance of Crystal Clear and Unclear Days to Evaluate Residual Interictal Burden in Patients With Migraine Treated With CGRP Monoclonal Antibodies.European journal of neurology · 2026Article
- Interictal burden, not ictal burden, drives work productivity impairment in headache disorders: insights from a Japanese cross-sectional study.The journal of headache and pain · 2026Article
- The Interictal State of Migraine: Understanding the Hidden Burden Between Attacks.Current pain and headache reports · 2026Review
- Adapting to life with chronic migraine: a qualitative study of lived experiences among multi-ethnic Asian patients.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Identifying Hidden Disability in Migraine Patients Using the Migraine Interictal Burden Scale-4.Cureus · 2025Article
- Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study.Journal of neurology · 2025Observational
- Observational
- The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.The journal of headache and pain · 2025Observational
- Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.Biomedicines · 2024Article
- Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine.Toxins · 2024Article
- Depression and the risk of fibromyalgia syndrome: a two-sample Mendelian randomization study.Frontiers in psychiatry · 2024Article
- Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.Frontiers in neurology · 2024Review
- Conceptualising migraine attacks from a biopsychosocial model using qualitative and functional behavioural analysis.Scandinavian journal of primary health care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious research has extensively documented the impact of migraine episodes ('ictal') on patients' health-related quality of life. Few studies have looked at the impact of migraine on migraine-free days ('interictal'). This study was designed to describe interictal burden of migraine in a mixed group of people affected by migraine and to explore patient characteristics associated with interictal burden.
methodsPeople with migraine in the United States (US) and Germany were recruited for a cross-sectional online survey, including a subgroup treated with calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). The survey included the Migraine Interictal Burden Scale (MIBS-4), Headache Impact Test (HIT-6), and items measuring patient demographics, clinical and treatment background. Data were analyzed using descriptive statistics and linear regression.
resultsFive hundred six people with migraine completed the survey (US: n = 257; Germany: n = 249), of whom 195 had taken a CGRP mAb for three or more months. Participants had a mean of 8.5 (SD = 6.4) Monthly Migraine Days (MMD) and 10.4 (SD = 7.1) Monthly Headache Days (MHD). The mean MIBS-4 score was 6.3 (SD = 3.4), with 67% reporting severe interictal burden (MIBS-4: ≥5). The mean HIT-6 score was 65.3 (SD = 6.0), with 86% reporting severe migraine impact (HIT-6: ≥60). MIBS-4 was correlated with the HIT-6 (r = 0.37), MMD and MHD (both r = 0.27). The HIT-6, MMD, MHD, CGRP mAb treatment, and depression all had an independent positive association with the MIBS-4.
conclusionTwo-thirds of the study sample reported substantial interictal burden. Whilst interictal burden was associated with migraine frequency and impact of migraine attacks, study results also show it represented a distinct aspect of the overall disease burden. Study findings further indicate unique associations between interictal burden and depression. A unique positive association between interictal burden and CGRP mAb treatment suggests a remaining unmet need among people affected by migraine treated with CGRP mAb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.